American technology firm Medidata, a subsidiary of Dassault Systèmes, will support clinical trials of Moderna’s Covid-19 vaccine candidate ‘mRNA-1273’ after the companies entered a partnership.

Medidata’s set of technologies will support in the development of Moderna’s mRNA-1273 clinical trials, which also includes the Phase III trial.

The Phase III trial is expected to enrol 30,000 participants.

With the help of Medidata’s Cloud platform for clinical development, teams from both companies are moving further with the urgency, which has been necessitated as a result of the global pandemic.

Medidata co-founder and co-CEO Tarek Sherif said: “We are proud to be working with Moderna on these breakthrough trials, which are so important to medical science and the health of our global society.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The extensive partnership we’ve built together over many years is allowing us to support these critical clinical studies. Clearly, the faster we can arrive at answers, the better it will be for everyone, everywhere.”

Medidata noted that this clinical trial incorporates data captured directly from participants, reducing the need for office visits.

The ‘virtualisation’ of the trial enables participants to use their own devices, relieving the burden of carrying a separate, ‘provisioned’ device.

Moderna chief digital and operational excellence officer Marcello Damiani said: “We are pleased to collaborate with Medidata.

“Medidata’s unified platform is helping us put participants at the center of our efforts to develop a safe and effective vaccine against Covid-19.”

In April this year, Medidata launched an advanced, intuitive platform called myMedidata for patients.

In February, Medidata and Project ALS entered a research partnership in order to develop new therapeutic strategies for the treatment of Amyotrophic lateral sclerosis (ALS).